U.S. Building Stock News

LKQ (LKQ) has initiated a formal review of its business after renewed pressure from activist investors, putting potential asset sales or even a full company sale on the table for shareholders. See our latest analysis for LKQ. LKQ's formal review comes after a tough run for long term holders, with a 1 year total shareholder return decline of 19.3% and a 3 year total shareholder return decline of 38.1%. At the same time, the 90 day share price return of 12.3% suggests momentum has recently...

WD-40 Company recently expanded its board of directors to 10 members by appointing Ken Plunk, a former J&J Snack Foods chief financial officer and long-time Wal-Mart executive, to serve on its Audit and Finance Committees effective February 18, 2026. This appointment brings extensive financial, international operations, and risk oversight experience to WD-40’s board, potentially strengthening governance around capital allocation, global expansion, and operational efficiency. Next, we’ll...

In February 2026, Glaukos Corporation reported past fourth-quarter and full-year 2025 results showing sales rising to US$143.12 million for the quarter and US$507.44 million for the year, alongside a larger net loss and a US$112,867,000 impairment of intangible assets, and it also issued 2026 net sales guidance of US$600 million to US$620 million. Glaukos has also filed a US$69.25 million shelf registration tied to an ESOP-related common stock offering, highlighting how the company is...

Why Church & Dwight is on investors’ radar today Church & Dwight (CHD) is drawing fresh attention after a period in which the share price and fundamentals have moved in different directions, prompting investors to reassess how the business is currently priced. The stock has returned about 8% over the past month and roughly 24% in the past 3 months, while the 1 year total return is a 6% decline. That split between recent momentum and longer term performance often leads investors to look more...

Capital Clean Energy Carriers Corp. recently priced a €250 million unsecured bond issue in Greece, maturing in 2033 with a 3.75% semi-annual coupon, and has also announced that its fourth-quarter 2025 financial results will be released on March 5, 2026. The bond proceeds earmarked for debt repayment, capital expenditure and working capital shed light on how CCEC is reshaping its balance sheet and funding future growth projects. We’ll explore how this €250 million unsecured bond issuance may...

DT Midstream, Inc. reported full-year 2025 results showing sales rising to US$1,243 million and net income to US$441 million, alongside a 7% dividend increase to US$0.88 per share and a US$396.99 million shelf registration for 3,000,000 shares related to its ESOP. Management’s disclosure that its project pipeline is several times larger than the announced US$3.40 billion capital plan, with growth expected to outpace a 7% annualized rate through the rest of the decade, points to a materially...

Institutional Buying Puts Parsons in Focus Bastion Asset Management’s new fourth quarter position in Parsons (PSN), totaling 128,186 shares worth about US$8.04 million, has put fresh attention on the contractor’s government and infrastructure exposure. See our latest analysis for Parsons. Parsons’ share price closed at US$67.86 after a 2.82% 1 day share price return. Despite an 18.12% 90 day share price decline, the 1 year total shareholder return of 22.60% and 5 year total shareholder return...

Viridian Therapeutics (VRDN) is in focus after reporting a larger than expected Q4 2025 loss and lower than forecast revenue. Its lead thyroid eye disease candidate remains under FDA Priority Review and EMA review. See our latest analysis for Viridian Therapeutics. At a share price of US$30.25, Viridian’s 1 day share price return of 2.96% and 7 day share price return of 7.77% follow a weaker 30 day share price return of an 8.33% decline. The 1 year total shareholder return of 109.92%...

Revvity (RVTY) has recently drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months and year. See our latest analysis for Revvity. With the share price at $95.59 and a 30 day share price return of 12.14% decline, recent weakness builds on a softer trend, as the 1 year total shareholder return of 13.16% decline and 3 year total shareholder return of 25.03% decline point to fading momentum despite...

Recent share performance and business profile Without a specific headline event driving trading activity today, Two Harbors Investment (TWO) has still drawn attention after a recent share price move, prompting investors to reassess its risk and income profile. The stock shows a 1 day return of around a 1% decline, with a 7 day move of about a 3% decline and a one month performance near an 11% decline, while the past 3 months sit modestly positive. Over longer periods, total returns are mixed,...

In February 2026, Stable Sea announced a partnership with dLocal to power low-cost, high-speed stablecoin-based B2B cross-border payments across more than 40 countries, using dLocal’s local payout rails. This collaboration highlights how dLocal is deepening its role in emerging-market payment infrastructure by combining its local rails with stablecoin settlement for large-ticket international transactions. Next, we’ll explore how integrating stablecoin rails into its cross-border platform...

Kadant Inc. recently reported its fourth-quarter and full-year 2025 results, showing quarterly sales of US$286.2 million and flat net income of US$24.03 million, alongside essentially unchanged earnings per share versus the prior year. For 2025 as a whole, Kadant’s sales were broadly stable at about US$1.05 billion, but full-year earnings per share from continuing operations eased, while management issued 2026 guidance that points to higher expected revenue and GAAP EPS. We’ll now examine...

Why Nektar Therapeutics Is On Investors’ Radar Today Nektar Therapeutics (NKTR) has caught investor attention after a period where its shares showed strong moves over the past month and past 3 months, contrasting with mixed shorter term returns. See our latest analysis for Nektar Therapeutics. At a share price of $68.36, Nektar’s recent 30 day share price return of 83.12% and year to date share price return of 57.44% sit alongside a very large 1 year total shareholder return. This suggests...

In February 2026, Travelers Companies launched its AI Claim Assistant, an agentic voice solution built on OpenAI models and APIs to handle auto damage claim calls, streamline submissions, and free claim professionals to focus on more complex issues while retraining call center staff into higher-value roles. The rollout highlights how Travelers is embedding advanced analytics and AI directly into its claims workflow, blending automation with live human support to potentially raise service...

What the No.3PLUS launch could mean for Olaplex Holdings (OLPX) Olaplex Holdings (OLPX) has launched No.3PLUS Complete Repair Treatment, a pre-shampoo product built on its Bond Building Technology and new Damage Defense Cationic Complex, supported by a broad retail rollout and a science themed marketing campaign. See our latest analysis for Olaplex Holdings. Despite today’s 5.6% one day share price decline, Olaplex’s 90 day share price return of 36.9% and 12.6% year to date gain suggest...

Oshkosh Defense recently announced a public-private partnership with the Marine Depot Maintenance Command to support advanced manufacturing, materiel support, and the Digital Manufacturing Exchange, enabling secure local production of validated vehicle parts for faster military repairs and improved fleet readiness. By sharing controlled technical data to authorize local part manufacturing while protecting intellectual property, Oshkosh is embedding itself more deeply in the U.S. military’s...

KeyCorp (KEY) is in focus after analysts revisited their views following recent quarterly results. At the same time, stubborn inflation data, credit risk worries, and a pickup in insider selling are tempering sentiment around the regional bank. See our latest analysis for KeyCorp. After a strong 14.39% 90 day share price return, KeyCorp’s 1 year total shareholder return of 30.36% contrasts with a slightly negative year to date share price move. This suggests momentum has cooled as inflation...

What Huntsman’s latest earnings mean for shareholders Huntsman (HUN) recently reported fourth quarter and full year 2025 results, showing lower sales and a larger annual net loss, developments that help explain the stock’s recent moves. For the fourth quarter, Huntsman reported sales of US$1,355 million compared with US$1,452 million a year earlier. The company posted a net loss of US$96 million, compared with a net loss of US$141 million in the prior year period. Basic and diluted loss per...

In recent days, CIBC initiated coverage on Brookfield Business Partners L.P. with an Outperformer rating, joining other brokers that have expressed confidence in the business. Analysts have highlighted Brookfield Business Partners’ connection to the broader Brookfield group, its cornerstone Clarios holding, and an apparent discount to net asset value as central to their positive view. We will now look at how this wave of bullish analyst coverage, especially around valuation and dealmaking...

Kenvue Inc. reported its fourth-quarter 2025 results, with sales rising to US$3,780 million and net income reaching US$330 million, while full-year sales eased to US$15.12 billion but net income increased to US$1.47 billion. At the same time, Schafer Cullen Capital Management exited its Kenvue position, citing ongoing pressures on consumer demand, inventory and distribution issues, and intensifying competition despite improved earnings. We’ll now assess how Kenvue’s earnings resilience...

Associated Banc-Corp (NYSE:ASB) has appointed Alexander Bush as Executive Vice President and Chief Data Officer. Bush will lead the company’s enterprise data strategy and governance across the organization. For investors watching NYSE:ASB, this move comes as the stock trades at $26.58, with a 1 year return of 13.8% and a 5 year return of 44.2%. Those figures indicate that the company has been taking steps to refine its business, and a dedicated data leader represents another layer in that...

In late February 2026, Crinetics Pharmaceuticals reported fourth-quarter 2025 revenue of US$6.16 million and a net loss of US$122.82 million, with full-year 2025 revenue of US$7.70 million and a net loss of US$465.32 million, alongside higher loss per share than the prior year. On the same day, the company filed a US$207.35 million shelf registration for up to 4,778,774 common shares tied to an employee stock ownership plan, highlighting both its growing capital needs and efforts to support...

Surgery Partners, Inc. has reported its fourth-quarter and full-year 2025 results, with sales rising to US$885.0 million for the quarter and US$3.31 billion for the year, while net loss narrowed to US$15.0 million in Q4 and US$77.9 million for 2025 compared with the prior year. Alongside this revenue growth, the company’s loss per share from continuing operations improved materially year over year, suggesting progress in its efforts to contain losses and improve operational performance. With...

On 27 February 2026, Nova Ltd.’s CFO, Guy Kizner, presented at the Susquehanna 15th Annual Technology Conference in New York, highlighting the company’s position in semiconductor process control. The conference appearance came as Nova was being recognized for multi‑year revenue and earnings growth, strong free cash flow margins, and high returns on invested capital, reinforcing its reputation for operational efficiency and quality in metrology. We’ll now explore how this fresh recognition of...